RBC Capital Reiterates Outperform Rating for Ascendis Pharma (NASDAQ: ASND) Following Strong Q2 2026 Results
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameAscendis Pharma A/S
-
Registration countryDenmark
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









